{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T12:12:57Z","timestamp":1697976777594},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":7140,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1987,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A prospective randomised study was conducted comparing the efficacy and toxicity of the antibiotics ticarcillin and cefamandole (TC) with or without tobramycin (TCT) in 100 febrile neutropenic patients with solid tumours undergoing conventional chemotherapy. In this study, neutropenia &lt;100\/\u03bcMl was noted in 31% of 106 evaluable infectious episodes and neutrophil counts &lt;1,000\/\u03bcMl persisted for a median 4 days. Infection was microbiologically documented in 42% of episodes (bacteremia 24%) with gram\u2010negative organisms responsible for 63% of bacterial isolates. Overall, 65% of episodes responded to TC and 76% to TCT (p&gt;0.05). Patients with initial shock bacteremia, pulmonary infection, or gram\u2010negative sepsis responded relatively poorly. Neutrophil nadir and pathogen susceptibility did not influence outcome. Antibiotic toxicity was minimal with no tobramycin\u2010related nephrotoxicity. These results are broadly comparable to those observed with leukemic patients, but the relatively short duration of neutropenia in the solid\u2010tumour patients appears to minimize the need for additional antibiotics provided there is adequate antimicrobial coverage with the initial choice of antibiotics.<\/jats:p>","DOI":"10.1002\/mpo.2950150103","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T16:10:23Z","timestamp":1171987823000},"page":"7-13","source":"Crossref","is-referenced-by-count":1,"title":["Randomised study of ticarcillin, cefamandole with or without tobramycin in febrile, neutropenic patients with solid tumors"],"prefix":"10.1002","volume":"15","author":[{"given":"Jonathan P.","family":"Page","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney S.","family":"Aroney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archinte.1975.00330050089015","article-title":"Clinical presentation of infection in granulocytopenic patients","volume":"135","author":"Sickles EA","year":"1975","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(75)80005-3"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197804)41:4<1610::AID-CNCR2820410452>3.0.CO;2-B"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/137.1.14"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90324-7"},{"key":"e_1_2_1_7_2","first-page":"87","article-title":"A multicenter comparative trial of moxalactam and ticarcillin versus tobramycin in ticarcillin in febrile neutropenic cancer patients","volume":"19","author":"Feld R","year":"1983","journal-title":"Proc Am Assoc Cancer Res and ASCO"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_1.S21"},{"key":"e_1_2_1_9_2","first-page":"177","article-title":"In vitro synergy of cefamandole tobramycin combination","volume":"50","author":"Valent AJ","year":"1977","journal-title":"Yale J Bio Med"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197307000-00002"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.227.1.45"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1200\/JCO.1983.1.10.597","article-title":"Combination of amikacin and carbencillin with or without cefazolin as empiric treatment of febrile neutropenic patients","volume":"1","author":"EORTC International Antimicrobial Therapy Project Group","year":"1983","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90217-X"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.10.2.241"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/137.Supplement.S25"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/137.Supplement.S139"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(78)90450-3"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0308-2261(21)00029-1","article-title":"Antibacterial therapy\u2010special considerations in neutropenic patients","volume":"5","author":"Rodriguez V","year":"1976","journal-title":"Clin Haematol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90242-0"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-64-2-328"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197603000-00006"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.141.7.926"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90669-6"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)91170-7"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90935-4"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197903000-00004"},{"key":"e_1_2_1_27_2","first-page":"1433","article-title":"Carbenicillin, cefazolin and amikacin as an empiric therapy for febrile granulocytopenic cancer patients","volume":"61","author":"Klastersky J","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90243-0"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.7.5.652"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90571-1"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950150103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950150103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T06:42:57Z","timestamp":1697870577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950150103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1987,1]]}},"alternative-id":["10.1002\/mpo.2950150103"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950150103","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,1]]}}}